Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Biosimilar Guidance Development Timelines Criticized By Docs And Patients

Executive Summary

FDA's user fee deal with sponsors sets target dates for documents on interchangeability, naming and labeling, but non-industry stakeholders urge agency to accelerate their release; guidance development efforts will get boost in BsUFA II with funding for new dedicated biosimilars unit starting in fiscal year 2018.

Advertisement

Related Content

Biosimilar Interchangeability: NOR-SWITCH-Type Study Not Enough For US FDA
Biosimilar Prescribing Decisions May Depend Upon Disease State
GDUFA II: Industry Shares Stage With FDA
How Risky Is Pfizer’s Launch Of Its Remicade Biosimilar?
Biosimilars Will Get PDUFA-Style Reviews Under New User Fee Plan
Biosimilar User Fee Agreement Puts FDA On Hook For Delayed Guidances
Biosimilar User Fee Agreement Offers FDA Funding Boost, Fee Structure Overhaul
FDA Proposes Dedicated Biosimilar 'Unit' For BsUFA II

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register